TB Alliance announces the appointment of David Greeley as Senior Vice President, External Affairs. Mr. Greeley will be responsible for TB Alliance's r...
The TB Alliance and its partners have completed patient enrollment in REMox TB, a global Phase III clinical trial, which may result in the registratio...
Prof. Charles Mgone Executive Director of the European and Developing Countries Clinical Trials Partnership (EDCTP) The enrolment of volunteers in t...
Dr. Martin Springsklee Vice President - Head Global Medical Affairs Anti-Infectives at Bayer HealthCare We started our partnership with the TB Allia...
Dr Stephen H. Gillespie MD DSc Sir James Black Professor of Medicine University of St Andrews University Chief Investigator For me, the completion...
Dr Jane Rahedi Ong’ang’o Community Engagement Coordinator Kenya Medical Research Institute (KEMRI), Nairobi, Kenya In January 201...
Dr. Tim McHugh Director University College London (UCL) Centre for Clinical Microbiology – REMox TB UCL Lead The microbiology laboratory...
“The GFINDER report shows a large retraction of public funding, especially for product development partnerships (PDPs), which will have devastat...
London – A fresh round of funding cuts from rich nations in the wake of the global financial crisis threaten the development of a new generation...
The meeting was convened to catalogue expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis. Phase 2 trials were define...
Press Contact: press@tballiance.org
Falling Short: Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis
New TB Regimens: What Countries Want
Pathway to Patients
Policy on the Compassionate / Emergency Use of Experimental TB Alliance Drugs